NCT01084655

Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer

An Open-label Phase 1/2 Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 38 (actual)
• Sponsor: Millennium Pharmaceuticals, Inc. · Industry
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is an open-label, multicenter, Phase 1/2 study of TAK-700 in combination with docetaxel and prednisone that will evaluate the safety and pharmacokinetics (PK) of the combination and will allow estimation of prostate-specific antigen (PSA) response in men with metastatic castration-resistant prostate cancer (mCRPC).

Conditions

• Prostate Cancer

Interventions

Type	Name	Description
DRUG	TAK-700	TAK-700 with docetaxel and prednisone on a continuous schedule.
DRUG	Docetaxel	TAK-700 with docetaxel and prednisone on a continuous schedule.
DRUG	Prednisone	TAK-700 with docetaxel and prednisone on a continuous schedule.

Timeline

• Start date: 2010-07-01
• Primary completion: 2013-01-01
• Completion: 2016-03-01
• First posted: 2010-03-10
• Last updated: 2019-07-30
• Results posted: 2019-07-30

Locations

1 site across 1 country: United States